|
Paul J. Lytle
Chief Financial Officer
Paul J. Lytle has served as Chief Financial Officer since August 2002 and has over 17 years of finance and accounting experience. Mr. Lytle oversees various functions, including finance and accounting, financial reporting, Corporate Governance, investor relations, human resources and information technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the Company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the Company’s Corporate Secretary in 2000. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a B.S. in Business Administration from the California State University at Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.
|
|
|
Joseph S. Shan, M.P.H.
Vice President, Clinical & Regulatory Affairs
Joseph S. Shan has served as Vice President, Clinical & Regulatory Affairs since March 2009 and previously served as our head of Clinical and Regulatory Affairs since January 2003. He is responsible for the design and execution of our clinical trials and overseeing regulatory submissions. Since joining Peregrine in 2000, Mr. Shan has been instrumental in advancing the clinical development of the Company's bavituximab and Cotara ® antibody products. Prior to joining Peregrine, Mr. Shan held positions of increasing responsibility in clinical and regulatory affairs at Edwards Lifesciences (formerly Baxter Healthcare Corporation) and Sulzer Medica. Mr. Shan received his B.S. degree in Physiological Sciences from the University of California, Los Angeles and his M.P.H. degree from the George Washington University in Washington, D.C. He is a member of the American Society of Clinical Oncology, the Association of Clinical Research Professionals and the Regulatory Affairs Professionals Society.
|
|
|
Shelley P. M. Fussey, Ph.D.
Vice President, Intellectual Property
Shelley P.M. Fussey, Ph.D. has served as our Vice President, Intellectual Property since February 2005. Dr. Fussey plays a key role in our U.S. and international patenting, patent analysis and patent defense. Dr. Fussey's expertise includes patent strategy for technologies developed both in-house and in-licensed from universities. She has broad experience in intellectual property consulting for areas including cancer treatment, immunology, and antiviral technology, as well as other areas central to pharmaceutical and biotechnology drug development. Prior to joining Peregrine, Dr. Fussey worked for the law firms of Williams, Morgan & Amerson and Arnold, White and Durkee. She holds a Ph.D. in Biochemistry and a B.Sc. in Biochemistry with First Class Honours (Summa Cum Laude) from the University of Newcastle upon Tyne, U.K.
|
|
|
Jeffrey L. Masten
Vice President, Quality
Jeffrey Masten has served as Vice President, Quality since 2011. Mr. Masten is responsible for the overall quality assurance program for both Avid and its parent company Peregrine. Prior to joining Avid, Mr. Masten has served as Senior Director, Head of Quality Assurance at two Genentech manufacturing sites. At Genentech from 2002 to 2011, he designed and implemented quality programs, spanning the bulk formulation and aseptic processing and fill/finish of biologics, and led regulatory inspections from domestic and international agencies. Prior to Genentech, he was Director, Quality Operations for Aventis Behring, which was acquired by CLS Behring. He began his 30-year career in quality assurance at Eli Lilly and Company. Mr. Masten earned a Master of Business Administration from the University of Notre Dame, a Bachelor of Science from Salisbury University, and completed chemistry and pharmacology graduate-level courses at Indiana University and Butler University, respectively.
|
|
|
Robert L. Garnick, Ph.D.
Head of Regulatory Affairs
Dr. Garnick has over 30 years of experience in Drug and biologic pharmaceutical development. He was formerly the Senior Vice President of Regulatory, Quality and Compliance at Genentech, Inc. Dr. Garnick spent 24 years at Genentech helping to found the biotechnology industry. While at Genentech Dr. Garnick was responsible for the approval of over 17 drugs, biologics and medical devices. He has extensive experience in analytical methodology, process validation, the regulatory review process both in the US and Europe and in Risk assessments. He has authored numerous scientific papers and has given numerous keynote presentations to the pharmaceutical Industry.
|
|
|
Kerstin B. Menander, M.D., Ph.D.
Head of Medical Oncology
Kerstin Menander, M.D., Ph.D. has been Peregrine’s Head of Medical Oncology since March 2011. She supports the planning and execution of Peregrine’s numerous clinical trials for oncology indications. Dr. Menander has 30 years of experience in drug development, having held senior positions in Abbott Laboratories, Syntex Laboratories, Introgen Therapeutics, Collagen Corporation, and Cell Pathways. At these companies, she led the clinical and regulatory strategy and development of drugs, biologics, and devices. She has led the international management of various clinical trials, which have supported 15 approvals for various indications in the U.S. and Europe including Lupron®, the leading therapy for the treatment of prostate cancer. Her regulatory experience includes leading the successful development of several INDs, IDEs, NDAs, BLAs (also accelerated), PMAs and conditional and regular MMAs. Dr. Menander earned her medical degree and Ph.D. in Histology from the University of Lund in Sweden.
|
|
|
Steven Chamow, Ph.D.
Head of Process Science
Steven Chamow, Ph.D. has over 20 years of experience in biopharmaceutical product development and has contributed to the development of Avastin®, Natrecor®, and Vectibix®. As Head of Process Science, Dr. Chamow leads a group responsible for the development of manufacturing processes for mammalian cell products for both Peregrine and third-party clients of Avid. Previously, he served as Senior Vice President, CMC at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics. Prior to Intradigm, Dr. Chamow was Vice President, Process Sciences at Genitope Corporation and at Abgenix, Inc., where he established the company’s process sciences department and helped lead the design and construction of its award-winning production facility in Fremont, CA. He has served as Director of Biopharmaceutical Development at Scios, Inc. and as a Scientist and Senior Scientist in Genentech’s Process Development department. He earned a B.A. in Biology from the University of California Santa Cruz, a Ph.D. in Biochemistry from the University of California Davis, and completed postdoctoral training at the National Institutes of Health. He is author or co-author of more than 45 scientific publications and patents and is co-editor of a 1999 book entitled Antibody Fusion Proteins.
|
|
|
Vladimir Evilevitch, M.D., Ph.D.
Medical Director
Vladimir Evilevitch, M.D., Ph.D. joins Peregrine as medical director from PAREXEL International, where he was associate medical director responsible for planning and executing clinical trials for cardiovascular and oncology programs. Previously, Dr. Evilevitch was the regional medical advisor for oncology at Novartis Healthcare, where he led Phase I through Phase IV clinical development programs in the Nordic region for a wide range of oncology therapeutics, including Femara® (breast cancer), Afinitor® (renal cell carcinoma), Glivec® (gastrointestinal stromal tumors), and Sandostatin® LAR® (neuroendocrine tumors). Prior to working in the pharmaceutical industry, Dr. Evilevitch was a chief attending physician and clinical assistant professor for the Diagnostic Center of Imaging and Functional Medicine in the Department of Nuclear Medicine at Malmoe University Hospital in Sweden. He earned his Doctor of Medicine (M.D.) and Doctor of Philosophy (Ph.D.) in Clinical Physiology and Nuclear Medicine from Lund University in Sweden. Additionally, Dr. Evilevitch completed a postdoctoral fellowship in the Department of Molecular and Medical Pharmacology of the Nuclear Medicine Clinic at the University of California, Los Angeles. He has published on a broad range of oncology and nuclear medicine research topics.
|
|
|
Mary J. Boyd, Ph.D.
Head of Business Development for Asia and Europe
Dr. Boyd has more than 20 years of international pharmaceutical and biotechnology business development experience with large pharmaceutical companies including GlaxoSmithKline, Novartis and Roche. Dr. Boyd was previously director, Asia, worldwide business development, R&D for GlaxoSmithKline; head of business development and licensing in Japan for Novartis; and head, licensing and patent group for Roche in Japan. In these positions, she identified new opportunities, negotiated global agreements and maintained productive relationships with other companies. Dr. Boyd holds a Ph.D. in Developmental Genetics from the University of Cambridge, UK and a B.Sc. in Biochemistry from the University of Sussex, UK.
|
|
|
|
